(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
26 August 2021 (26.08.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/168349 A1

(51) International Patent Classification:
A61K 9/08 (2006.01) *A61K 31/498* (2006.01)
A61K 31/4184 (2006.01) *A61P 27/06* (2006.01)

(21) International Application Number:
PCT/US2021/018906

(22) International Filing Date:
19 February 2021 (19.02.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/979,214 20 February 2020 (20.02.2020) US

(71) Applicant: **ALLERGAN, INC.** [US/US]; 2525 Dupont Drive, Irvine, CA 92612 (US).


(72) Inventors: **GRAHAM, Richard**; 5066 Balsawood, Irvine, CA 92612 (US). **WU, Ke**; 61 Pinestone, Irvine, CA 92604 (US). **FAHID, Massoud**; 930 Verona Drive, Fullerton, CA 92835 (US). **DIBAS, Mohammed**; 1658 Honors Circle, Corona, CA 92883 (US).

(74) Agent: **BASS, Jonathan, Y.** et al.; Allergan, Inc., 2525 Dupont Drive, Irvine, CA 92612 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: PHARMACEUTICAL COMPOSITIONS OF ALPHA-2-ADRENERGIC RECEPTOR AGONISTS AND THEIR USE FOR IMPROVING VISION



(I)




FIG. 1

(57) Abstract: Methods of using the alpha-2-adrenergic receptor agonist of Formula (I): for improving vision such as in the treatment of ocular conditions such as presbyopia, poor night vision, visual glare, visual starbursts, visual halos, and some forms of myopia (e.g. night myopia) are described.

[Continued on next page]

WO 2021/168349 A1

Published:
— *with international search report (Art. 21(3))*